Navigation Links
Gen-Probe to Webcast Presentation at Leerink Swann Molecular Diagnostics Conference
Date:3/27/2008

SAN DIEGO, March 27 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO) announced today that the Company will present at the Leerink Swann "Bugs and Drugs: The Future of Molecular Diagnostics Roundtable Conference" in New York on April 3, 2008 at approximately 1:20 p.m. Eastern Time. The presentation is scheduled to be webcast live and may be accessed through a link on the investor information section of Gen-Probe's website at http://www.gen-probe.com. The webcast will be available for 30 days following the event.

About Gen-Probe

Gen-Probe Incorporated is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests (NATs) that are used primarily to diagnose human diseases and screen donated human blood. Gen-Probe has approximately 25 years of NAT expertise, and received the 2004 National Medal of Technology, America's highest honor for technological innovation, for developing NAT assays for blood screening. Gen-Probe is headquartered in San Diego and employs approximately 1,000 people. For more information, go to http://www.gen-probe.com.

Caution Regarding Forward-Looking Statements

Any statements in this press release about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any f
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Gen-Probe to Webcast Presentation at Deutsche Bank Small- and Mid-Cap Growth Conference
2. Gen-Probe to Webcast Presentation at 26th Annual JPMorgan Healthcare Conference
3. Gen-Probe to Webcast Presentation at NASDAQ 20th Investor Program
4. Jorgine Ellerbrock Joins Gen-Probe as Senior Vice President, Operations
5. 3M, Gen-Probe to Discontinue Molecular Food Testing Collaboration
6. BD Announces Live Webcast of Second Fiscal Quarter Earnings Conference Call
7. Webcast Alert: Lifeway Foods, Inc. Announces 2007 Year End Full Financial Results
8. Response Biomedical Corp. - Year End 2007 Earnings Webcast and Conference Call - March 31, 2008
9. Novadaq to hold fiscal 2007 year-end and fourth quarter results conference call and webcast
10. Smart Balance to Webcast Presentation at Citi Small/Midcap Conference
11. Exelixis Announces March 19 Webcast of Presentation at the Lehman Brothers Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)...linical trial results could lead to availability o...eatment for deep lines and wrinkles by 2009. , ... 24, 2008 -- Gel-Del Technologies , a St. Paul, M... that it has concluded clinical trials of CosmetaL...als say holds potential to be a more effective alt...
(Date:7/24/2008)...ll/ --, Key Highlights, Misys plc (LSE: MSY) del...sing targets for the next phase of the turnaround....%, bringing Group operating profit(2) to GBP81m,3...trategy and entering,into the next phase of the tu...o view the Multimedia News Release, please click:,...
(Date:7/23/2008)...wire/ -- MediVoice(R), LLC, the,world,s first mobi...escribing, has formed a strategic partnership with... web-based, patient-centered health record,managem...e and market its,mobile voice-activation solution ...., "MediVoice is pleased to develop a strategic p...
(Date:7/23/2008)..., July 23 /PRNewswire-FirstCall/ - Cardiome Pharma...t it has entered into an,agreement with CR Intrins...,CR Intrinsic Investors, LLC, an affiliate of S.A....ertible preferred shares for gross proceeds of,US$... for general corporate,purposes, costs associated ...
Breaking Medicine News(10 mins):Health News:Clinical Trial Concluded For New Wrinkle Treatment 2Health News:Clinical Trial Concluded For New Wrinkle Treatment 3Health News:Misys Announces Preliminary Results for the Year Ended 31 May 2008 2Health News:Misys Announces Preliminary Results for the Year Ended 31 May 2008 3Health News:Misys Announces Preliminary Results for the Year Ended 31 May 2008 4Health News:MediVoice(R) Partners With VisionTree(R) to Integrate Its Voice-Activated e-Prescribing Solution Into VisionTree's VTOC(TM) Web-Based Patient Management System 2Health News:MediVoice(R) Partners With VisionTree(R) to Integrate Its Voice-Activated e-Prescribing Solution Into VisionTree's VTOC(TM) Web-Based Patient Management System 3Health News:Cardiome Announces Preferred Share Financing 2Health News:Cardiome Announces Preferred Share Financing 3
.... Ragnfrid H. Nordbo, of the Norwegian Institute o...d set of people// suffering anorexia nervosa, a fo...his mental disease attribute a great deal of impor...a deep seated need or emotion. In his estimate, t...
...n, 81, the famous Pulitzer Prize-winning novelist,...usetts.// According to his daughter, Alexandra, he... He belonged to Virginia. He was obsessive about r...im write novels like "Lie Down In Darkness" and "T...
...a government data, the number of deaths due to alc...The Office for National Statistics (ONS) revealed ... in the year 1991 and it has risen to 8,386 by las...s, the lower price and easy accessibility are resp...
...hich has been one of the major causes of death in ...and in the next two decades// according to the Chi...Dr Harry Burns, "In the 1960s, one in 100 men died...ing all the time and, thanks to the smoking ban, I...
Other Medicine News:Health News:Deaths due to heavy drinking has doubled in 15 years 2Health News:Eradication of Lung Cancer in 20 years 2Health News:Eradication of Lung Cancer in 20 years 3
(Date:7/22/2008)...y Demonstrates Feasibility and Efficacy of Treatin...iver Cancer, SAN FRANCISCO, and YONGIN-SI, South ... Francisco, CA and Ottawa, Ontario), and its South... that novel findings from,a Phase I clinical trial...rated that the product was well-tolerated and resu...
(Date:7/22/2008)...TH SAN FRANCISCO, Calif., July 22 /- ...t has completed patient enrollment,in its Phase 1/...ity and,ammonia scavenging effects of HPN-100 (for...ylbutyrate) in patients with urea cycle disorders,...lts in the fourth quarter,of this year., (Logo: ...
(Date:7/22/2008)...HIA ANTIPOLIS, France, July 22 /PRNewswire-FirstCa...unced it has successfully completed the,enrollment...ed hypertension,in two clinical pharmacology studi...nnounced timelines. These trials are designed to a...n comparison to ibuprofen and,naproxen, using the ...
(Date:7/21/2008)... YORK, July 21 /- Ari Kiev, M.D., pre... speaker at the upcoming conference Wall,Street Un...ement,s Guide to,Wall Street. The conference will ...errace, 267 Fifth Avenue in New York. The event is...d mid-cap life science companies to gain,better in...
Breaking Medicine Technology:Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 2Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 4Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 2NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 3Coherent Inc to Webcast First Fiscal Quarter 2008 Results 9937 1Dave Perbix Named Vice President Occupational Health Sales and Marketing for Kaiser Permanente 9933 1Dave Perbix Named Vice President Occupational Health Sales and Marketing for Kaiser Permanente 9933 2Vapotherm 28R 29 Announces Validation of U S Patent 2694 1Vapotherm 28R 29 Announces Validation of U S Patent 2694 2Clinimetrics Celebrates 20th Anniversary in Contract Research Business 2690 1
...FirstCall/ -- Vical,Incorporated today announced t...d positive results following interim analysis of d... 3 trial of an,angiogenesis product candidate usin...ndings that the primary efficacy,endpoint in the t...ce and that there were no major safety concerns re...
...AMADEO, one of the,first studies to compare the p...ockers in hypertensive patients with,diabetic nep...f Hypertension, Milan. The results from this study...ignificantly greater extent,than losartan.(1) ...ss, Foothills Hospital,in Calgary, Canada said "T...
Other Medicine Technology:Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan 2Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan 3Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan 4Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan 5New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 2New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 3New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 4New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 5
Anti Gliadin IgA Enzyme Immunosay for quantitative determination of Gliadin-IgG antibodies in serum.
...igned as a high throughput primary or backup instr...r offers performance and reliability equal to or g...advanced technology of the AUTION JET AJ-4270 and ...ate results, limiting interference from elevated p...
Assay uses highly specific rabbit anti-estriol antibody reparation - negligible cross-reactivity with other estrogen metabolites. Excellent assay precision and reproducibility. Superior sensitivity
...rone Sulfate (E1S) is the most abundant circulatin... men [1,2]. Estrone Sulfate is a major metabolite ...fe in blood [2,3]. In premenopausal women, estrone...e and estradiol, rising gradually during the folli...
Medicine Products: